Streetbeat News

Products Services

BBIO

BridgeBio Pharma has announced a potential path for accelerated approval in the U.S. for BBP-418, a therapy for Limb-girdle Muscular Dystrophy Type 2I, based on FDA discussions. The company has also dosed the first patient with LGMD2I/R9 in its Phase 3 FORTIFY clinical trial of BBP-418 and is in the process of opening sites in Europe and Australia.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:36 am

NIO

Chinese electric vehicle maker Nio Inc has opened its 1600th power swap station in China, adding 100 stations in about a month. The company aims to add 1,000 battery swap stations by year-end, taking the total to 2,300. Nio's CFO Steven Feng expressed confidence that more power swap stations will lead to more sales growth. However, Nio recently announced it would no longer provide free battery-swapping services to new buyers after reporting revenue that missed consensus and deeper losses for Q1.

Portfolio Pulse from Anan Ashraf

July 31, 2023 | 11:30 am

IONS

Ionis Pharmaceuticals has completed enrollment in the Phase 3 CARDIO-TTRansform study of Eplontersen in patients with Transthyretin-mediated Amyloid Cardiomyopathy. The study enrolled over 1,400 patients.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:16 am

DGX

Quest Diagnostics (NYSE: DGX) has introduced the AD-Detect™ Test for Alzheimer's Disease, the first consumer-initiated blood test for assessing potential risk of developing Alzheimer's disease. The test is available for purchase on questhealth.com.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:15 am

MRNS

The European Commission has approved Marinus Pharmaceuticals' Ztalmy (Ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with Cyclin-dependent kinase-like 5 deficiency disorder in patients aged two to 17 years.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:14 am

RNAZ

Transcode Therapeutics has announced positive results for its lead therapeutic candidate, TTX-MC138, in non-human primates. The therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:12 am

TFFP

TFF Pharmaceuticals and Uniphar Durbin Ireland have opened an expanded access program for Voriconazole Inhalation Powder, a treatment for pulmonary aspergillosis and other voriconazole responsive fungal pulmonary infections.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:10 am

TNXP

Tonix Pharmaceuticals has initiated enrollment in the Massachusetts General Hospital (MGH) Phase 2 'STROBE' study of TNX-1900, an intranasal potentiated oxytocin, for the treatment of binge-eating disorder.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:09 am

RDHL

Redhill Biopharma's RHB-107 (Upamostat) has been accepted for inclusion in a multinational platform trial for early Covid-19 outpatient treatment. The trial, supported by the U.S. Government, will be conducted in the U.S., Thailand, Ivory Coast, and South Africa. The Phase 2 study, predominantly funded by the U.S. Government Department of Defense, has received FDA clearance to start and is estimated to be completed by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:08 am

EVAX

Evaxion Biotech has presented results on EVX-B1, an AI-designed vaccine against Staphylococcus Aureus. The vaccine has shown high protection against S. Aureus disease in preclinical animal models.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:06 am